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Abstract
AIM
To assess the accuracy of shear wave elastography
(SWE) alone and in combination with aminotransferase
platelet ratio index (APRI) score in the staging of liver
fibrosis.

Informed consent statement: Informed voluntary consent was
acquired from all the study participants.

METHODS
A multicenter prospective study was conducted to
assess the accuracy of SWE (medians) and APRI to
predict biopsy results. The analysis focused on distingui
shing the different stages of liver disease, namely, F0
from F1-4, F0-1 from F2-4, F0-2 from F3-4 and F0-3
from F4; F0-F1 from F2-F4 being of primary interest.
The area under the receiver operating characteristic
(AUROC) curve was computed using logistic regression
model. The role of age, gender and steatosis was also
assessed.
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RESULTS
SWE alone accurately distinguished F0-1 from F2-4 with
a high probability. The AUROC using SWE alone was
0.91 compared to 0.78 for using the APRI score alone.
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is not exhaustive but this paper focuses on the last
four causes. Liver fibrosis is characterized by excessive
accumulation of extracellular matrix due to the release
of inflammatory mediators and free radicals to cause
oxidative stress and liver fibrogenesis. During this process
hepatic stellate cells activation occurs. Platelet derived
growth factor, tumor necrosis factor α, transforming
growth factor β or reactive oxygen species play a role
in the progression to liver fibrosis. Several phenotypic
[4]
alterations occur with the end result being irreversible .
The current gold standard in the diagnosis and staging
of liver fibrosis is liver biopsy. Liver biopsy and more
recently ultrasound guided liver biopsy only evaluates
1/50000 of the liver parenchyma. It is invasive, has
a complication rate (albeit small,) and is subject to
[5]
intra and inter-observer variability . Because of the
imperfect nature of liver biopsies, over the last several
years there has been a growing trend to validate noninvasive tools to diagnose and stage liver fibrosis.
Alkaline aminotransferase platelet ratio index (APRI)
is a laboratory marker that has been shown to have
some value but is inferior to liver biopsy. Ultrasound
and magnetic resonance have been used for elasticity
imaging. Magnetic resonance elastography, even though
promising, has some disadvantages. Aside from the
significant cost of the study, it cannot be performed
in a liver with iron overload because of signal-to-noise
limitations; has longer examination times compared to
ultrasound elastography, and is subject to respiratory
[6]
artifact . Ultrasound elastography has been validated
and has been shown in many studies to have similar
[5,7]
sensitivity and specificity to liver biopsies .
Ultrasound elastography measures the liver stiffness/
elasticity by assessing at least 100 times the proportion
of the liver that a biopsy does. Transient elastography
[8]
(TE) has been validated in multiple studies but
shear wave elastography (SWE) may be preferred
because unlike transient elastography, which consists
of a vibrator producing shear waves, the latter can
perform a conventional ultrasound at the same time.
The technique is integrated into an ultrasound system.
The principle behind the interpretation of shear wave
elastography is that shear waves produced by a focused
ultrasound beam are directly related to the stiffness
[5,7,8]
of the liver from where they are generated
. SWE
is also reportedly more accurate than TE in assessing
[8,9]
significant fibrosis (≥ F2) . The use of shear wave
elastography in the diagnosis and staging of liver fibrosis
has been increasing. Being a non-invasive technique
proves advantageous because repeat measurements
can be obtained in patients with chronic progressive
liver diseases. However, this non-invasive procedure
does have some pitfalls. It is subject to intra- and interobserver variability, validated cut-offs have mainly
only been demonstrated in hepatitis C; Acute hepatitis
can have false positives. In patients with a high body
mass index, erroneous values may be obtained. A very
practical pitfall is confounding factors such as edema,
inflammation, cholestasis and congestion. All these

The APRI score, when used in conjunction with SWE,
did not make a significant contribution to the AUROC.
SWE and steatosis were the only significant predictors
that differentiated F0-1 from F2-4 with an AUROC of
0.944.
CONCLUSION
Our study validates the use of SWE in the diagnosis and
staging of liver fibrosis. Furthermore, the probability of
a correct diagnosis is significantly enhanced with the
addition of steatosis as a prognostic factor.
Key words: Shear wave elastography; Aminotransferase
platelet ration; Liver fibrosis; Liver biopsy
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: The gold standard in the diagnosis and staging
of liver fibrosis is an invasive liver biopsy. The accuracy
of non-invasive tools such as ultrasound shear wave
elastography either alone or in combination with the
use of the aspartate transaminase platelet ratio index
score compared to histology to guide management of
liver fibrosis is not known. We addressed this question
in a multicenter trial in patients with chronic progressive
liver disease in a low to middle income country.
Sande JA, Verjee S, Vinayak S, Amersi F, Ghesani M. Ultrasound
shear wave elastography and liver fibrosis: A Prospective
Multicenter Study. World J Hepatol 2017; 9(1): 38-47 Available
from: URL: http://www.wjgnet.com/1948-5182/full/v9/i1/38.htm
DOI: http://dx.doi.org/10.4254/wjh.v9.i1.38

INTRODUCTION
Liver fibrosis is a progressive condition that if diagnosed
early and staged accurately, allows early clinical inter
vention that may arrest or slow down progression to
end stage decompensated cirrhosis. The spectrum of
chronic liver disease and fibrosis that leads to end stage
decompensated cirrhosis, is an important cause of
[1]
morbidity and mortality in the world . Early diagnosis,
accurate staging and re-evaluation of liver fibrosis is aimed
at avoiding the progression from normal to minimal to
significant fibrosis and timely management of patients
with advanced disease.
There are several chronic progressive liver diseases
that lead to liver fibrosis. Non-alcoholic fatty liver
disease (NAFLD) is one of the most common. NAFLD is
closely associated with obesity and insulin resistance.
Pathological changes in the biochemical profile of the
liver that lead to liver fibrosis also occur due to chronic
metabolic conditions such as diabetes and degenerative
[2,3]
conditions like atherosclerosis . Other common causes
of liver fibrosis include infections such as chronic viral
hepatitis and human immunodeficiency virus. Drugs
and other toxins also play an important role. This list
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must be put in context and a multidisciplinary clinical
[5,7,8,10]
approach used in the interpretation of the results
.
A limitation of prior studies is the lack of integration
of the accuracy and limitations of elastography. No prior
study has combined elastography with the use of APRI
and histology to guide management of liver fibrosis.
This study addresses the gaps and makes practical
inferences that focus on accurate early diagnosis and
staging. The focus in our study is “interpretation within a
clinical context”. This multi-institutional study performed
in Kenya aims to capture and highlight factors based
on the disease burden in this region. Ultrasound elasto
graphy has only recently been made available in East
Africa. The findings, therefore, could be of wider benefit
because of the high burden of other etiologies of liver
disease such as hepatitis B in the region. Most studies
thus far have been carried out in the West with the
disease burden focused on hepatitis C. In addition,
the literature largely reports data from middle-high
economic areas whereas adherence to clinical guidelines
may not be as feasible in poor/resource challenged
facilities.

analysis performed at AKU department; and (3) referral
for a liver biopsy request to be analyzed at the Pathology
department of Kenyatta National Hospital.
At recruitment, a study file was opened for each
patient by the principle investigator at the AKU. Routine
liver function tests, platelet counts, and demographic
information related to confounding factors of chronic
liver disease, including information on alcohol use,
Human Immunodeficiency Virus status, viral load and
CD4 levels, hepatitis B and C status was collected. Men
who had been drinking more than 30 g of alcohol per
day and women who had been drinking more than 20 g
of alcohol per day were considered current drinkers.
Patients who had stopped drinking completely for more
than six months before the biopsy were considered ex[11]
drinkers .
At the AKU routine ultrasound of the liver was per
formed to qualitatively record presence (grade 0-3) or
absence of steatosis using established criteria published
[12]
by Lupşor-Platon et al . Any other diffuse or focal
lesions were documented followed by SWE. At AKU
elastography measurements were taken from the
[13]
right lobe
of the liver with the patients holding their
breath. Measurements were considered successful
[14]
using validated criteria established by Castéra et al :
“(1) 10 valid shots; (2) a ratio of valid shots to the total
number of shots of 60% or higher; and (3) variability
of measurements less than 30% of the median value
of liver stiffness measurements”. Philips iU22 ultra
sound machine with its C5-1 curvilinear transducer
was used. The units for SWE readouts (liver stiffness)
were kilopascals (kPa). Four sonologists each with more
than 5 years’ experience in routine liver scanning and
validated ultrasound elastography experience from
uniform training performed each exam independently. The
median stiffness (used to grade the fibrosis), average
stiffness and standard deviation of measurements
generated by the software were recorded and inter
[7,10]
preted by the four sonologists independently
. Each
patient had one liver biopsy specimen taken from the
[13]
right lobe
after the ultrasound elastography which
was graded histologically for fibrosis based on the
[15,16]
. This was done by
Metavir classification system
two experienced histopathologists at the AKU and KNH
Pathology departments. Each specimen was evaluated by
the two histopathologists from each respective pathology
department. Discrepancies were resolved by consensus
between the two. The histopathologists from the two
sites were full-time faculty, certified by the Kenya Medical
Practitioners and Dentists Board, practicing in University
Hospitals each with greater than ten years’ experience
in liver biopsy assessment for fibrosis. In each patient
the time interval between ultrasound, elastography
and histology was not more than one month. The path
ologists and sonologists were blinded to clinical data and
elastography or histology grade.
Interpretation of liver fibrosis by shear wave elasto
graphy in kPa divided the entity into no fibrosis (F0), mild
fibrosis (F1), severe fibrosis (F2), significant fibrosis (F3)

MATERIALS AND METHODS
Objectives

The primary objective was to analyze the accuracy of
shear wave elastography in comparison to liver biopsy
in differentiating the various stages of liver fibrosis. The
secondary objective was to evaluate whether the addition
of the APRI score to SWE would improve the accuracy
of this differentiation. With these, illustrate the role of
the shear wave elastography, APRI score, and biopsy
solely and or in combination in the diagnostic algorithm
of accurate quantification of liver fibrosis. We also sought
to assess the role of other covariates, namely, age,
gender and steatosis, and their influence on the relative
importance of SWE and the APRI score in predicting the
extent of liver fibrosis.

Design

Three hospitals were included in this prospective study:
Aga Khan University (AKU) Hospital, Kenyatta Teaching
and Referral Hospital and St Mary’s Mission Hospital.
Approval was obtained from the relevant Scientific and
Ethics committees. All consecutive patients referred for
an ultrasound guided liver biopsy at all three institutions
were subject to recruitment based on the inclusion and
exclusion criteria as well as informed written consent.
The study included patients above eighteen years of age
with chronic progressive diffuse liver disease. Patients
were excluded from the study if they did not have any of
the three diagnostic tests, i.e., liver biopsy, APRI score or
SWE.
Consecutive patients were recruited by the principle
investigator in three ways: (1) referral for an ultrasound
guided liver biopsy at the AKU Radiology Department; (2)
referral from St Mary’s Hospital with biopsy performed
by the AKU Radiology department and pathological

WJH|www.wjgnet.com
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Table 1 Summary illustrating sample size calculation above
AUROC
0.8
0.8

Total (n ) % Positive
110
130

30
30

# Positive

# Negative

SE

33
39

77
91

0.050
0.046

Confidence interval
Lower

Upper

0.701
0.709

0.899
0.891

AUROC: Area under the receiver operating characteristic.

Summary of elastography average
Mean
3.4
4.5
Min
0.5
1.3
Max
5.8
6.2
35.0

6.4
3.2
14.4

9.0
5.2
12.7

the APRI score and the covariates age (categorized as
below and above the median), gender and steatosis.
Besides the P-values, the analysis provided the ORs
and their respective 95%CI limits. The sensitivity and
the specificity were computed based on the variables
included in the model. This in turn enabled the ROCs
and the AUROC to be determined. Summary statistics
and correlation coefficients, where appropriate, were
computed.

15.1
2.2
34.5

Elastography average

30.0
25.0
20.0
15.0
10.0

RESULTS

5.0
0.0

0

1

2

3

Demographics and baseline characteristics

One hundred and twenty-eight patients were recruited
for the study. AKU, KNH and St. Mary’s contributed
54 (42.2%), 53 (41.4%) and 21 (16.4%) patients, re
spectively. The most prevalent viral infection was hepatitis
B that was noted in 30 (23.4%) patients. This was
followed by human immunodeficiency virus (HIV) with
18 (14.1%) and hepatitis C with 13 (10.2%) patients
(Appendix 1); fifteen patients had 2 or more infections.
Sixty-three (49.2%) of the patients had a steatosis score
of 0 and 61 (47.7%) of the patients had a histology
fibrosis score of 0. Eighty-one (63.3%) patients fell in the
histology fibrosis score subgroup F0-1; the remaining 47
(36.7%) fell in the F2-F4 subgroup. Fifty percent of the
patients had an elastography score of F0 and 59 (46%)
of the patients the APRI score of F0 (Appendix 2). The
elastography median scores were the lowest among
HIV subjects followed by those with hepatitis B and then
a hepatitis C infection. The highest scores were from
those with multiple viral infections. The APRI scores also
follow the pattern described above for the elastography
median scores (Appendix 3). There appears to be a
good correlation between the elastography median
scores and the histology fibrosis scores (Appendix 4).
The elastography and APRI fibrosis score are statistically
significantly correlated with the histology fibrosis scores
(Appendix 5) (Figure 1 and Table 2).

   4

Histology fibrosis scores

Figure 1 Elastography average vs histology fibrosis score (Box Plot).

and cirrhosis (F4). Automatic median value generated
by the ultrasound software was used to establish the
elastography grade as follows < 4.6 = F0, 4.6-5.6 = F1,
[10,17-19]
5.7-7.0 = F2, 7.1-12.0 = F3 and > 12 = F4
. APRI
score was calculated using a formula proposed by original
[20]
study of Wai et al : APRI = [(AST level/ULN)/platelet
9
counts (10 /L)] × 100. A score of < 0.5 was graded as
F0, 0.5-1.5 as F1-3 and > 1.5 as F4. The corresponding
[21,22]
histology grade was assessed
.

Sample size estimates

The sample size was determined with the aim to keep
the standard error of the AUROC at 0.05. This set the
difference between the upper and lower 95%CI limits to
0.20 (± 2 standard errors). From previous publications
the range for the AUROC for significant fibrosis, as deter
mined from non-invasive tests, is approximately 0.69 to
0.89; for cirrhosis the range is from 0.81 to 0.98. Assum
[20]
ing the AUROC to be approximately 0.8
the sample
size of 110 patients would yield a standard error of 0.05
(Table 1).
Shear wave elastography has been shown to have
a lower operator error technique than transient elasto
[23-25]
graphy (3%-16%)
. As a precautionary measure we
raised the sample size from 110 to 130.

Logistics regression results

Table 3 summarizes some of the key results that stem
med from the analysis of the SWE median and APRI
score data using logistic regression. Both variables show
a high degree of statistical significance in their individual
ability to distinguish between the lower stages of fibrosis
compared to the higher stages. This is true across all
possible partitions of the Metavir fibrosis scores. However,
the AUROCs for SWE medians are much higher than

Statistical analysis

The statistical review of the study was performed by
a biomedical statistician. Logistic regression models
with backward elimination, using SAS version 9.3,
were utilized to assess the significance of SWE median,

WJH|www.wjgnet.com
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Table 2 Summary of liver disease scores by histology fibrosis score (discrete variables) n (%)
Histology fibrosis scores
Elastography fibrosis score
F0
F1
F2
F3
F4
APRI fibrosis score
0
1 to 3
4
Steatosis
Grade 0
Grade 1
Grade 2
Grade 3

Total

χ2
P value

0 (n = 61)

1 (n = 20)

2 (n = 20)

3 (n = 10)

4 (n = 17)

(n = 128)

51 (83.6)
10 (16.4)
0 (0.0)
0 (0.0)
0 (0.0)

7 (35.0)
10 (50.0)
3 (15.0)
0 (0.0)
0 (0.0)

5 (25.0)
2 (10.0)
9 (45.0)
3 (15.0)
1 (5.0)

0 (0.0)
2 (20.0)
1 (10.0)
7 (70.0)
0 (0.0)

1 (5.9)
1 (5.9)
0 (0.0)
1 (5.9)
14 (82.4)

64 (50.0)
25 (19.5)
13 (10.2)
11 (8.6)
15 (11.7)

< 0.0001

45 (73.8)
14 (23.0)
2 (3.3)

6 (30.0)
13 (65.0)
1 (5.0)

6 (30.0)
9 (45.0)
5 (25.0)

1 (10.0)
9 (90.0)
0 (0.0)

1 (5.9)
8 (47.1)
8 (47.1)

59 (46.1)
53 (41.4)
16 (12.5)

< 0.0001

48 (78.7)
6 (9.8)
6 (9.8)
1 (1.6)

8 (40.0)
8 (40.0)
2 (10.0)
2 (10.0)

2 (10.0)
5 (25.0)
7 (35.0)
6 (30.0)

1 (10.0)
1 (10.0)
4 (40.0)
4 (40.0)

4 (23.5)
1 (5.9)
0 (0.0)
12 (70.6)

63 (49.2)
21 (16.4)
19 (14.8)
25 (19.5)

< 0.0001

APRI: Aminotransferase platelet ratio index.

Table 3 Shear wave elastography median and aminotransferase platelet ratio index score to differentiate between metavir subgroups

SWE median

APRI score

SWE and APRI1

P value
OR
95%CI
AUROC
P value
OR
95%CI
AUROC
AUROC
APRI influence

F0-3 vs F4

F0-2 vs F3-4

F0-1 vs F2-4

F0 vs F1-4

< 0.0001
1.708
1.379, 2.115
0.926
0.0202
1.511
1.067, 2.141
0.812
0.927
0.001

< 0.0001
1.789
1.432, 2.236
0.929
0.039
1.404
1.018, 1.938
0.784
0.931
0.002

< 0.0001
2.983
1.839, 4.838
0.908
0.0005
3.482
1.727, 7.018
0.780
0.920
0.012

< 0.0001
2.683
1.789, 4.025
0.879
0.0008
4.651
1.895, 11.416
0.803
0.890
0.011

1
SWE median and APRI score. OR: Odds ratio; SWE: Shear wave elastography; APRI: Aminotransferase platelet ratio index; AUROC: Area under the
receiver operating characteristic.

those for APRI score.
The SWE median differentiates the Metavir fibrosis
subgroups F0-1 and F2-4 with an AUROC of 0.908
compared to 0.780 for the APRI score. These results
imply that the SWE on its own is a better predictor of the
differentiating the subgroups than the APRI score. When
we utilize both variables simultaneously, the increase
in the AUROC attributed to the APRI score is less than
1.2% higher than that predicted by SWE median. This
amounts to about 13% of the 9% not predicted correctly
by the SWE median. The results for other partitions of
the histology fibrosis scores mimic those described above
with the AUROC for SWE median being around 0.9 and
that of the APRI score being about 0.8.
Additional logistic regression models incorporated
several other variables in the analysis to evaluate their
impact on the AUROC. The variables considered, in
addition to the SWE median and the APRI score were
the covariates age (categorized as below and above
the median), gender and steatosis score. The results of
the logistic regression analysis (Table 4) with all of the
aforementioned variables in the model showed that SWE
and the steatosis score were the only two variables that

WJH|www.wjgnet.com

made significant contributions to the predictive power of
the model.
Using the backward elimination method, all of the
variables that were not making a significant contribution
at the 0.1 level were dropped from the model. The
results of these analysis (Table 5) show that for the
primary objective of differentiating between F0-1 and
F2-4 is accomplished quite well with an AUROC of 0.944;
the two variables that made a significant contribution
were SWE and steatosis. The steatosis score adds
significantly to the prediction model that tries to identify
the fibrosis group that a patient belongs to (Table 5);
this is true in every case except for the F0-3 vs F4
partition. The APRI score on the other hand makes a
significant contribution to only the partition F0-2 vs F3-4.
Given that the APRI score appears in only one partition
as an important predictor, an additional analysis was
performed by dropping the APRI score from the model.
This resulted in adding a few additional observations to
the data set used for analysis since missing APRI scores
had contributed to a slightly reduced sample size. In
addition, the steatosis score was added to the F0-3 vs F4
model in order to have a unique set of predictors across
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Table 4 Prediction of histology fibrosis score (Grouping: F0-1 vs F2-4) using elastography median, aminotransferase platelet ratio
1
index score, age category , sex and steatosis maximum likelihood and odds ratio estimates
Variable
Intercept
Age category
LE median
APRI score
Elastography median
Sex
Female
Steatosis

2

DF

Coefficient
estimate

Standard
error

Wald χ

1
1
1
1
1
1

-6.6482
0.0971
0.1946
0.9041
0.3330
1.1317

1.3510
0.3219
0.3873
0.2513
0.3551
0.3462

24.2158
0.0910
0.2526
12.9464
0.8797
10.6843

Pr > χ

2

< 0.0001
0.7629
0.6153
0.0003
0.3483
0.0011

OR estimate

Lower 95%CI limit
for OR

Upper 95%CI limit
for OR

1.214
1.215
2.470
1.947
3.101

0.344
0.569
1.509
0.484
1.573

4.288
2.595
4.042
7.830
6.112

1

Age category (years): n = 128. Mean (SD) 46 (16.99). Median 42; Minimum 18; Maximum 108. OR: Odds ratio; APRI: Aminotransferase platelet ratio index.

Table 5 Significance of predictive values associated with key
pre-identified variables

Table 6 Elastography median and steatosis
Variable

F0-3 vs F4
SWE median
APRI score
Age
Gender
Steatosis
AUROC

< 0.0001
NS1
NS
NS
NS
0.926

Pr > χ

2

F0-2 vs F3-4 F0-1 vs F2-4 F0 vs F1-4
< 0.0001
0.0404
NS
NS
0.0263
0.962

0.0003
NS
NS
NS
0.0002
0.944

F0-3 vs F4
Intercept
Elastography median
Steatosis
AUROC = 0.936
F0-2 vs F3-4
Intercept
Elastography median
Steatosis
AUROC = 0.954
F0-1 vs F2-4
Intercept
Elastography median
Steatosis
AUROC = 0.944
F0 vs F1-4
Intercept
Elastography median
Steatosis
AUROC = 0.902

0.0002
NS
NS
NS
0.0007
0.902

1

NS: Not significant at the 0.1 level. SWE: Shear wave elastography; APRI:
Aminotransferase platelet ratio index; AUROC: Area under the receiver
operating characteristic.

all partitions. These results are presented in Table 6. The
fact that the results from Tables 5 and 6 are very similar
implies that the missing data points did not influence the
outcome in any meaningful way.
The F0-2 vs F3-4 data shows that the AUROC ob
tained with the use of the SWE median and the steatosis
score is 0.954 (Table 6). By adding the APRI score
(Table 5) the AUROC increase of 0.008 or 0.8%. This
represents a decrease of about 13% (0.008 of 0.046)
in the error rate. On the other hand, adding steatosis to
the model after including the SWE median and the APRI
score, the AUROC increase from 0.931 (Table 3) to 0.962
(Table 5), an increase of 0.031 or 3.1%. This represents
a decrease of about 44.9% (0.031 of 0.069) in the error
rate.

< 0.0001
< 0.0001
0.6529

1.681
1.187

1.347
0.563

2.099
2.502

< 0.0001
< 0.0001
0.0568

1.684
1.846

1.353
0.982

2.097
3.467

< 0.0001
0.0003
0.0002

2.397
3.135

1.500
1.703

3.828
5.772

< 0.0001
0.0002
0.0007

2.221
2.496

1.463
1.473

3.370
4.230

OR: Odds ratio; AUROC: Area under the receiver operating characteristic.

followed by those with hepatitis B infection; the next
highest score was for patients with a hepatitis C infection.
The lowest score was from those with multiple infections.
The APRI scores also follow the pattern described above
for the elastography scores. This pattern corresponds
with what has previously been described. Hepatitis C
most likely has higher levels of quantified liver fibrosis
because of the three viruses it has the most indolent
and chronic clinical course. The mortality from these
infections is correlated to chronic liver disease and not
due to progression of the virus due to the success of
[27,28]
antiretroviral therapy
.
Analysis categorized fibrosis as, F0 vs F1-4, F0-1 vs
F2-4, F0-2 vs F3-4, F0-3 vs F4. The results focus on F0-1
vs F2-4 which is of most clinical significance (no and nonsignificant fibrosis vs significant fibrosis that demands
intervention). There is a good correlation between the
elastography median scores and the histology fibrosis
scores. The OR of 3.0 implies that the elastography
median scores are 3 times more likely to correctly identify
a fibrosis score of F2-4 compared to F0-1. The upper and
lower limits for the OR with 95%CI do not cross 1 which

DISCUSSION
Summary of findings

The infection with the highest prevalence was hepatitis
B. There were also patients with HIV, hepatitis C and
the co-infections in this cohort. While the prevalence of
hepatitis B, C and HIV in Sub-Saharan Africa has not
[26]
been conclusively established , it has been postulated
that hepatitis B is relatively more prevalent than hepatitis
C as compared to the western world where hepatitis
[27]
C is more prevalent . Most studies on liver fibrosis
quantification have been carried out in the western world
therefore it is important to have the same studies carried
out in Sub-Saharan Africa where the epidemiology of the
viral infections is likely to be different. The elastography
median scores were the lowest among HIV subjects
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Figure 2 Prediction of histology fibrosis score (Grouping: F0-F1 vs F2-F4)
using elastography median. ROC: Receiver operating characteristic.
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1.00

Figure 3 Prediction of histology fibrosis score (Grouping: F0-1 vs F2-4)
using elastography median, aminotransferase platelet ratio index score,
age categor, sex and steatosis.

strengthens this result. However, the limits are wide
1.8-5. This may be due to the small sample size and
because close to 50% of the sample at F0. If F0 were
to be eliminated from the analysis this may reduce the
limits with a questionable effect on clinical significance.
The accuracy of the elastography median depends on
the sensitivity and specificity. This is clear from the raw
data used to generate the ROC curve. An elastography
median of approximately 3.8 is the point at which you
get the best sensitivity matched with specificity. The ROC
curve for model, which depicts sensitivity and specificity,
illustrates how for a very high sensitivity, specificity is low
and as sensitivity reduces; one arrives at a point where
specificity is acceptable clinically. That is, one can identify
disease with a high sensitivity and be correct (specifically
know that you are also picking the non-diseased). The
AUROC for the elastography median was 0.91. The
elastography and APRI fibrosis score are statistically
significantly correlated with the histology fibrosis scores.
However, APRI score in itself or when combined with
elastography median score does not significantly increase
the accuracy of elastography in the differentiation of nonsignificant vs significant fibrosis. APRI had an AUROC
of 0.78. APRI and elastography median had an AUROC
of 0.92. Therefore APRI does not have a statistically
significant effect on the prediction of F0-1 from F2-4
when added to elastography. And when used alone it is
significantly less accurate than elastography. However in
patients with chronic progressive liver fibrosis who need
repeated analysis to categorize and monitor the progress
of liver fibrosis APRI does have a clinically significant role
in the management algorithm of liver fibrosis.
Previous studies vary on the accuracy of elastography.
The sensitivity, specificity and diagnostic accuracy of
shear wave elastography in the determination of liver
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0.25
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stiffness compared with biopsy results is comparable
[8-10]
to
. The accuracy of elastography mirrors those
depicted by these studies albeit a slightly higher accu
racy in this study. This may be due to the difference in
grouping of the fibrosis scores for analysis. Also, if the
F0 of this study are removed from the analyses this
may lead to more similar figures since the F0 constitute
approximately 50%. The diagnostic accuracy of shear
wave elastography and APRI score in the determination
[8-10]
of liver stiffness has not been reported before
.
Ordinal regression and backward elimination was
used to analyze significance of HIV, hepatitis B, alcohol
use, steatosis, age and gender. It showed that steatosis
has a significant OR and P-value in the analysis for
[10]
fibrosis. Ferraioli et al showed that steatosis does not
affect the performance of elastography. The challenge as
stated in this paper is the confounding effect of various
pathologies in the diagnosis and staging of liver fibrosis.
This is particularly relevant in the generation and given
the wide use of reference ranges for all modalities
used in the diagnosis and staging of liver fibrosis. It is
for this reason that to date several studies have used
[8,10,17-19]
variable reference ranges for F0-F4
. Our results
highlight the potential effect of the presence of steatosis
(EF-S_1_10_3_Logistic_All Variables_F0-F1VsF2-F4
document) on the diagnosis and characterization of liver
fibrosis. Of note from this result is the increase in the
AUROC from 0.91 (Figure 2) to 0.95 (Figure 3) in the
logistic regression backward elimination analysis that
is attributable to the elastography median and steatosis
each with a significant P-value and OR (Table 4). This is an
area that needs further study, especially since steatosis
was measured subjectively in this study. The data on
HIV and alcohol use as variables were not adequately
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Begin with ultrasound elastography result
< F2

> F2

Liver fibrosis

US elastography
Diagnosisand
monitoring

Biopsy for baseline of chronic
progressive condition,
decide on whether to intervene
or not

When elastrography > F2, Biopsy

Follow clinically plus with, APRI
and elastrography

Biopsy again to reestablish
baseline or when considering
change in intervention

US guided liver
biopsy. Diagnosis

Figure 5 Flow chart depicting use of diagnostic tests in liver fibrosis. Begin
with US SWE result. US: Ultrasound; SWE: Shear wave elastography; APRI:
Aminotransferase platelet ratio index.

APRI score.
Coplimentary
monitoring

graphy. Technical and interpretation skill for elastography
specifically when choosing the ten values to include in
the report; this includes excluding/ignoring far outliers,
though these outliers may represent focal areas of diffe
rent fibrotic stages! Use of the median to give a final
conclusion of the ten chosen readings is appropriate
especially in the setting of variable readings. But, care
must be exercised. There should be a low threshold to
recommend a biopsy (still the gold standard) to confirm
the findings especially if the mean elastography reading is
in keeping with a diagnosis of no fibrosis yet the standard
deviation is high in the presence of individual readings of
[5]
cirrhosis . The challenge of the heterogeneously fibrotic
liver or presence of lesions, e.g., metastasis causing
heterogeneity of the liver rendering fibrosis assess
ment questionable in terms of using just the median to
conclude on the level of fibrosis especially when there
is a big difference in the individual stiffness values must
be remembered. These issues red flag the danger of not
allowing room to vary an impression and advise further
evaluation with an United States guided liver biopsy to
[5]
correlate . Indeed, one must also bear in mind that
the suggestion to further evaluate with a liver biopsy is
inherently flawed because of the attend pitfalls of the
tool. Chronic progressive liver fibrosis needs accurate
early diagnosis and interval monitoring. Elastography is
a validated tool. APRI can be used as a complimentary
tool though its effect is not of statistical significance but
clinical significance. Biopsy remains the gold standard.
We propose a flow chart at diagnosis. Further, the pro
bability of a correct diagnosis is significantly enhanced
with the addition of steatosis as a prognostic factor (Figure 5).

Figure 4 Link between diagnostic tests used in the evaluation of liver
fibrosis. US: Ultrasound; APRI: Aminotransferase platelet ratio index.

powered to add to this analysis.

Strengths

This study is timely because of the growing use of elas
tography in the developed world. In the developing
world the use of this diagnostic tool needs to grow via
an evidence based approach that is tailored to the local
disease burden. Most research in the west has focused
on hepatitis C and alcohol or nonalcoholic steatosis. The
wider disease burden covered in this study is thus a
more homogenous representation of chronic liver fibrosis
pathology. The complimentary use of APRI score is
especially relevant in resource limited setups.

Theoretical and practical implications of these findings

This study brought to light theoretical implication of the
need to standardize the diagnosis and accurate staging
and follow-up of liver fibrosis. Figure 4 depicts the link
between all tests used in the evaluation of liver fibrosis
(Figure 4).
The use of all tests should be complimentary and
histology has its place but the noninvasive tests may be
more logical in the beginning and for progressive moni
toring. Inference from the results generates a flowchart
below describing a management algorithm (Figure 5).

Limitations and problems encountered in the method

Inference from the results: Consider the following
flowchart at diagnosis

The number of ultrasound guided liver biopsies for the
assessment of liver fibrosis has continued to reduce
because of the increasing use of elastography which is
noninvasive and without the side effects associated with

Practical unique and reported challenges exist. Care
needs to be taken in interpretation and training for elasto
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Follow-up clinically plus with, APRI
and elastrography
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liver biopsy. This diagnostic trend is reinforced by the
[5,7,10,12]
continued validation of elastography
. Therefore
during this study the recruitment rate was low. As such
participants were recruited from three different sites to
meet the sample size requirement to adequately power
the results. The ultrasound and elastography where all
performed at the same site (AKU). Biopsy results were
analyzed by pathologists at two of the three sites (AKU
and KNH). This may have potentially led to variable
histological inter-observer variability. To counter this
each sample was read by each pathologist at each
respective site and discrepant values were resolved
by consensus. However, major and minor discrepancy
analyses of histology for inter-observer discrepancies
were not assessed.
There are limitations associated with elastography,
including the confounding effects of inflammatory activity,
[13]
and to a lesser extent, steatosis , on liver stiffness
evaluation. There is also reduced accuracy observed
in lower fibrosis stages (F0-F2). Furthermore, the inci
dences of failed and unreliable scans have been reported
to be approximately 3% to 16% in transient elastography
but less in shear wave elastography (figures not reported
[22]
yet) . The sample size was inflated by 5% to cater for
th
this. A typical liver biopsy covers 1/10000 of the liver
while elastography covers a larger area. Matching the
two sites covered by the two exams may not have been
100%.
The information sort in the data collection form to
analyze the secondary objectives was sensitive in nature
including queries about alcohol use and HIV status. This
precluded complete disclosure from participants and led
to inadequate data on related parameters. This led to a
reduction in the power of inferences regarding the role
of alcohol and HIV.

COMMENTS
COMMENTS
Background

Chronic progressive liver diseases cause liver fibrosis whose end result is
decompensated liver failure. Liver fibrosis that results from these diseases can
be reversed if diagnosed early. The current gold standard in the diagnosis of
liver fibrosis is a liver biopsy preferably ultrasound guided, which is an invasive
procedure with limitations and risks. Recent research have validated the use of
shear wave ultrasound based liver elastography which is a non-invasive imaging
based tool that has a sensitivity and specificity that almost parallels histological
diagnosis from a liver biopsy. The staging of liver fibrosis at diagnosis uses a
Metavir scoring system that has been adapted by elastography. Aminotransferase
to platelet ratio index is a liver function test that has some usefulness in the
diagnosis of liver fibrosis. The combined use of histology, elastography and
aminotransferase to platelet ratio index has not been elucidated.

Research frontiers

Previous studies have shown that ultrasound based elastography can substitute
liver biopsy in the accurate diagnosis of liver fibrosis.

Innovations and breakthroughs

This is the first study to evaluate the combined role of ultrasound based
elastography, histology and aminotransferase to platelet ratio index in a low to
middle income country for the management of progressive liver fibrosis.

Applications

The use of the three tests should be complimentary and histology has its
place but the noninvasive tests may be more logical in the beginning and for
progressive monitoring. More comprehensive analysis needs to be done to further
reveal the extent of confounding factors affecting the use of elastography in the
diagnosis and staging of liver fibrosis. Further work needs to be done to describe
the in cooperation of magnetic resonance elastography in the diagnostic algorithm
of liver fibrosis.

Terminology

Elastography is radiological based software that can diagnose and quantify the
degree of liver fibrosis. It is either ultrasound or magnetic resonance based.
Ultrasound bases elastography uses sound have to assess for and quantify
liver stiffness that is directly related to liver fibrosis. Aminotransferase to platelet
ratio is a laboratory parameter derived from part of the routine liver function
tests and platelet count.

Suggestions for improvement and further work

Peer-review

This has been an East African experience: Unique cha
llenges and similar differences to those published. More
comprehensive analysis needs to be done to further
reveal the extent of confounding factors affecting the
use of elastography in the diagnosis and staging of liver
fibrosis. The role of steatosis needs further objective
assessment. Further work needs to be done to describe
the in cooperation of magnetic resonance elastography in
the diagnostic algorithm of liver fibrosis.
Our study validates the use of ultrasound shear wave
elastography in the diagnosis and staging of fibrosis
within the context of liver disease in a LMIC.

The authors have validated the use of ultrasound shear wave elastography in
the diagnosis and staging of fibrosis within the context of liver disease in a low to
middle income country. Practical management algorithms that in cooperate the
use of ultrasound based elastography, histology and aminotransferase to platelet
ratio index have been demonstrated. More comprehensive analysis needs to
be done to further reveal the extent of confounding factors affecting the use of
ultrasound or magnetic resonance based elastography.
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